1. Home
  2. BLNK vs CALC Comparison

BLNK vs CALC Comparison

Compare BLNK & CALC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Blink Charging Co.

BLNK

Blink Charging Co.

HOLD

Current Price

$0.58

Market Cap

94.6M

ML Signal

HOLD

Logo CalciMedica Inc.

CALC

CalciMedica Inc.

HOLD

Current Price

$0.63

Market Cap

88.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
BLNK
CALC
Founded
2009
2011
Country
United States
United States
Employees
N/A
N/A
Industry
Industrial Specialties
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
94.6M
88.3M
IPO Year
2008
2020

Fundamental Metrics

Financial Performance
Metric
BLNK
CALC
Price
$0.58
$0.63
Analyst Decision
Hold
Buy
Analyst Count
5
2
Target Price
$1.95
$10.00
AVG Volume (30 Days)
1.5M
459.7K
Earning Date
05-11-2026
03-03-2026
Dividend Yield
N/A
N/A
EPS Growth
38.94
N/A
EPS
N/A
N/A
Revenue
$126,197,000.00
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
$17.87
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.54
$0.46
52 Week High
$2.65
$7.20

Technical Indicators

Market Signals
Indicator
BLNK
CALC
Relative Strength Index (RSI) 36.72 33.10
Support Level N/A $0.49
Resistance Level $0.72 $0.79
Average True Range (ATR) 0.03 0.09
MACD -0.01 0.10
Stochastic Oscillator 28.00 25.83

Price Performance

Historical Comparison
BLNK
CALC

About BLNK Blink Charging Co.

Blink Charging Co is an owner, operator, and provider of electric vehicle (EV) charging services. The company offers both residential and commercial EV charging equipment, enabling EV drivers to easily recharge at various location types. The company's business is the sale and distribution of electric vehicle charging equipment and its associated revenues earned from customers and/or Property Partners who use equipment connected to its network. It earns a majority of revenue from U.S.A.

About CALC CalciMedica Inc.

CalciMedica Inc is a clinical-stage biopharmaceutical company focused on developing therapeutics that treat serious illnesses driven by inflammatory and immunologic processes and direct cellular damage. Its product candidates act upon calcium release-activated calcium (CRAC) channels and would constitute a new class of drugs. Its product candidate is Auxora, a potent and selective intravenous formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys.

Share on Social Networks: